As you may have heard by now, ad revenue alone isn't enough to sustain ongoing efforts to improve our service, which is why we are asking loyal site users like you for help. For every $25 contribution, we're offering 3 months of premium service on a "non-recurring" basis. By reducing the need to click, scroll and wait for pages to load, some of our most popular features save premium members considerable time on every visit. Imagine saving even 2 or 3 minutes each day (to say nothing of 5 or 10 or more). Of course, only you know what your time is worth, so we'll let you do the math & figure out if a test drive makes sense for you. To learn more, click this link to watch a 2-min video tour of our premium service.
Re: To Any Expert with knowledge of Clinical Trial Analysis
Good points; I agree that the OS results from F1 in this subgroup are by far the most promising data out of the publically released topline data. I would want to see some evidence that this OS signal is directly related to the characteristics of MS: perhaps it is related to the much lower toxicity of MS compared to chemo, and we'll probably see if this affected the duration patients were able to sustain therapy shortly. I believe that Anna B. hinted that they will have an updated OS readout for ESMO, and hopefully the OS signal is maintained.
